Insider trades
Open-market buys and sales that US company officers, directors and 10% owners file, newest filing first.
| Trade type | ||||||||
|---|---|---|---|---|---|---|---|---|
Crescent BiopharmaCBIO | Open-market sale10b5-1 plan | 06/22 | 06/23 | 42,305 sh | $17.99 | $761,066.95 | −13.1% | |
Ryan LynchSEE REMARKS | Crescent BiopharmaCBIO | Open-market sale10b5-1 plan | 06/22 | 06/23 | 465 sh | $17.99 | $8,365.35 | −3.2% |
Crescent BiopharmaCBIO | Open-market sale10b5-1 plan | 06/22 | 06/23 | 1,112 sh | $17.99 | $20,004.88 | −5.2% | |
Jonathan McNeillPresident and COO | Crescent BiopharmaCBIO | Open-market sale10b5-1 plan | 06/22 | 06/23 | 20,549 sh | $17.99 | $369,676.51 | −12.9% |
Ellie Eunkyung ImChief Medical Officer | Crescent BiopharmaCBIO | Open-market sale10b5-1 plan | 06/22 | 06/23 | 1,219 sh | $17.99 | $21,929.81 | −5.2% |
Barbara Harlin BisphamSEE REMARKS | Crescent BiopharmaCBIO | Open-market sale10b5-1 plan | 06/22 | 06/23 | 1,218 sh | $17.99 | $21,911.82 | −5.9% |
Jan PinkasChief Scientific Officer | Crescent BiopharmaCBIO | Open-market sale10b5-1 plan | 06/22 | 06/23 | 1,288 sh | $17.99 | $23,171.12 | −5.5% |
Peter Evan HarwinDirector | Crescent BiopharmaCBIO | Open-market buy | 25/12/04 | 25/12/08 | 1,360,000 sh | $13.41 | $18,237,600 | +98.0% |